Delenex Therapeutics Closes $14M Series A Funding Round
Delenex Therapeutics AG completed its Series A funding round at CHF 13.5 million ($14 million). SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners led the financing. Delenex is a Zurich-Schlieren, Switzerland-based biotechnology company that develops therapeutic antibody fragments.
12 November 2010•4 mins read
